AI for Personalized Content Experiences ✌️【Career Counseling】✌️Invest ₹500 in blockchain and watch your profits multiply monthly. AI for Personalized Content Experiences - Invest Smart Grow Fast ✌️【Career Counseling】✌️Earn massive monthly returns. Start investing with ₹500 today!

AI for Personalized Content Experiences ✌️【Career Counseling】✌️Invest ₹500 in blockchain and watch your profits multiply monthly.Pharmaceutical giant Dr Reddy’s Laboratories (DRL) saw its shares surge 4.34% on Thursday in an otherwise sluggish market, reaching an intraday high of Rs 1,330.45 following an upgrade by Nomura.The Tokyo-based brokerage has upgraded the stock from ‘Neutral’ to ‘Buy’ with a revised target price of Rs 1,500, down from Rs 6,499, factoring in the 1:5 stock split on October 28.“We assess that risk-reward is favourable and thus upgrade the stock to Buy (from Neutral).

AI for Personalized Content Experiences ✌️【Career Counseling】✌️Invest ₹500 and watch your wealth grow with cutting-edge investment strategies.We reduce FY25/26F earnings by 13%/14% to factor in higher overhead costs.

Note that changes to our earnings estimates and target price are due to DRL’s 1:5 stock split,” said Saion Mukherjee and AmlanJyotiDas, research analysts at Nomura.They also said the relative underperformance of the stock suggests that concerns about the high contribution of generic cancer drug gRevlimid are already priced in.

“We think the Street is concerned about the higher contribution from gRevlimid, which could start declining in FY26F.

Further, the overheads have increased significantly in the recent past.

In the first half of FY25, R&D/SG&A were higher by 29%/27% year-on-year.”While the stock has underperformed theNifty PharmaIndex over the past five years, the upgrade reflects Nomura’s confidence in Dr Reddy’s ability to overcome near-term challenges and capitalise on future opportunities.

AI for Personalized Content Experiences ✌️【Career Counseling】✌️Unlock the power of smart investing with just ₹500. Watch your profits grow!The stock has risen only 13% over the past year, compared to the Nifty Pharma Index’s 36% growth.

AI for Personalized Content Experiences ✌️【Career Counseling】✌️Start small, grow big. Invest ₹500 and enjoy high returns every month!The underperformance persists despite a 22.AI for Personalized Content Experiences ✌️【Career Counseling】✌️Invest ₹500 in blockchain and earn up to 100% returns monthly.